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16RESEARCH Open AccessCharacterization of CDKN2A(p16) methylation and
impact in colorectal cancer: systematic analysis
using pyrosequencing
Michel P Bihl1, Anja Foerster1, Alessandro Lugli2* and Inti Zlobec2Abstract
Background: The aim of this study is to analyse CDKN2A methylation using pyrosequencing on a large cohort of
colorectal cancers and corresponding non-neoplastic tissues. In a second step, the effect of methylation on clinical
outcome is addressed.
Methods: Primary colorectal cancers and matched non-neoplastic tissues from 432 patients underwent CDKN2A
methylation analysis by pyrosequencing (PyroMarkQ96). Methylation was then related to clinical outcome,
microsatellite instability (MSI), and BRAF and KRAS mutation. Different amplification conditions (35 to 50 PCR cycles)
using a range of 0-100% methylated DNA were tested.
Results: Background methylation was at most 10% with ≥35 PCR cycles. Correlation of observed and expected
values was high, even at low methylation levels (0.02%, 0.6%, 2%). Accuracy of detection was optimal with 45 PCR
cycles. Methylation in normal mucosa ranged from 0 to >90% in some cases. Based on the maximum value of 10%
background, positivity was defined as a ≥20% difference in methylation between tumor and normal tissue, which
occurred in 87 cases. CDKN2A methylation positivity was associated with MSI (p = 0.025), BRAF mutation (p <
0.0001), higher tumor grade (p < 0.0001), mucinous histology (p = 0.0209) but not with KRAS mutation. CDKN2A
methylation had an independent adverse effect (p = 0.0058) on prognosis.
Conclusion: The non-negligible CDKN2A methylation of normal colorectal mucosa may confound the assessment
of tumor-specific hypermethylation, suggesting that corresponding non-neoplastic tissue should be used as a
control. CDKN2A methylation is robustly detected by pyrosequencing, even at low levels, suggesting that this
unfavorable prognostic biomarker warrants investigation in prospective studies.
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The CDKN2A gene is located on chromosome 9p21 and
encodes p16INK4a, a protein that functions to inhibit
CDK4 and 6 within the cell cytoplasm. In colorectal epi-
thelium, increased expression of p16INK4a may result
from mutation of BRAF leading to oncogene-activated
cell senescence [1,2]. Reversal of the senescence pheno-
type can be accomplished by hyper-methylation of the
promoter region leading to the subsequent development
of sessile serrated adenomas and possibly to carcinomas* Correspondence: alessandro.lugli@pathology.unibe.ch
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reproduction in any medium, provided the orwith high-level CpG Island Methylator Phenotype
(CIMP) [3].
CDKN2A promoter hypermethylation has been
described in 12-51% of colorectal cancers and is often
included in the panel of markers used to assess the
CIMP phenotype [4]. Age-related methylation has been
documented and likely represents a confounding factor
in the assessment of tumor-specific methylation and
subsequently the correlation of hypermethylation with
outcome [5]. Most studies to date evaluating CDKN2A
and patient outcome have done so using methylation-
specific PCR or MethyLight assays [4]. To date, pyrose-
quencing has only infrequently been used for methylation
analysis of genes involved in colorectal cancer progression,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for methylation analysis for several reasons. It is a quan-
titative method that generates a percentage of methyla-
tion at a given CpG site by calculating the ratio of C/T
(methylated to unmethylated C) in a sample [6]. Many
different CpGs can be analysed at the same time, which
allows specific sites and their potential clinical relevance
to be studied separately. Internal controls can be in-
cluded to determine inaccuracies resulting from in-
complete bisulfite conversion. ln the case of CDKN2A,
where a certain degree of age-related methylation in nor-
mal colonic mucosa may occur, the quantitative nature
of the pyrosequencing method allows one to account for
background methylation to provide a more accurate as-
sessment of tumor-specific hypermethylation.
The aim of this study is to evaluate site-specific
CDKN2A methylation patterns in both tumor and
matched non-neoplastic tissues, amplification conditions
and to propose a threshold value for CDKN2A methyla-
tion “positivity” by pyrosequencing. In a second step, we
evaluated the impact of CDKN2A methylation on clin-
ical outcome in a series of 432 patients with colorectal
cancers.Methods
Patients
Four hundred and thirty-two patients with primary colo-
rectal cancer were entered into this study. Clinico-
pathological information for each patient included age,
tumor location, gender as well as pT, pN, tumor grade,
histological subtype, vascular invasion, tumor growth
pattern, tumor budding and the tumor border configur-
ation. For all patients, information on survival could be
obtained. Median follow-up and survival time were
55.0 months and 60.0 (95%CI46-74) months, respect-
ively. Previously investigated molecular parameters
included MSI status, BRAF and KRAS mutation, which
were available for 395, 382, and 408 patients, respect-
ively. Ethical consent was obtained from the local ethics
committee.DNA isolation
Archival tissue blocks from each patient were obtained.
DNA was extracted from both primary tumours and the
adjacent non-neoplastic tissues from blocks with >70%
tumor cell content using NucleoMag 96 Tissue Kit
(Macherey Nagel) protocol and processed in the Xiril X-
100 robot (Xiril, Hombrechtikon, Switzerland). Appro-
priate regions of interest were identified from H&E
slides, marked using two different colors by an experi-
enced gastrointestinal pathologist (A.L.) and macrodis-
sected using a punching instrument.DNA denaturation and bisulfite conversion
DNA denaturation and bisulfite conversion were pro-
cessed into one-step using the EZ-96 DNA Methylation-
GoldTM Kit (Cat. No. D5007, ZYMO RESEARCH
CORP.). Briefly, 130 μl of the CT conversion reagent
were added to 20 μl of each DNA sample in a conver-
sion plate. The plates were sealed with the provided film
and the conversion plate transferred to a thermal cycler
running under the following steps: 98°C for 10 minutes,
53°C for 4 hours, storage at 4°C. 400 μl of M-Binding
Buffer were added to the wells of a Silicon-A™ Binding
Plate. After transfer to the wells of the Silicon-A™ bind-
ing plate, samples were centrifuged. Each well of the
plate was washed using 400 μl of M-wash buffer. After
centrifugation, 200 μl of M-Desulphonation buffer was
added to each and the plate was placed at room
temperature for 20 minutes followed by centrifugation
(3,000 x g for 5 minutes). Two consecutive steps includ-
ing washing (400 μl of M-wash Buffer) and centrifuga-
tion (3,000 x g for 5 minutes) were performed. The
Silicon-A™ binding plate was placed onto an elution
plate and 30 μl of M-Elution buffer was directly added
to each well. 5 minutes later, the samples were centri-
fuged at 3,000 x g for 3 minutes to elute the DNA. For
control of DNA methylation, Universal Methylated
Human DNA Standard was used (Cat. No. D5011,
ZYMO RESEARCH CORP).
Polymerase chain reaction (PCR)
The following primers for CDKN2A were used: Forward
ATGGAGTTTTYGGTTGATTGGT (region: 21964802–
21964781), reverse CCCRCCATCCCCTACTCC (region:
21964655–21964638); nested forward ATGGAGTTTTY
GGTTGATTGGT, Reverse Biot-CCCTCTACCCACCTA
AAT (region: 21964682–21964665), sequence primer
GGAGTTTTAGGTTGATTGGTT. Amplicon length
was 98 bp. For all 432 patients the methylation status of
CDKN2A was the result of a first and semi-nested PCR.
Each PCR began with a unique denaturation step for
11 min at 95°C followed by 45 cycles including de-
naturation, annealing and elongation at 95°C for 20 sec,
52°C for 15 sec, and 72°C for 20 sec respectively. The
final elongation step was done at 72°C for 7 min.
Preparation of samples for pyrosequencing
Three μl of Sepharose beads were mixed together with
40 μl of binding buffer and 22 μl of water and mixed in
an Eppendorf tube. Sixty μl of this mix was added to
20 μl of PCR products in a 96 well plate and agitated at
1400 rpm for 5 minutes. The PyroMark Q96 Plate was
filled with 0.3 μM of sequencing primer in 40 μl of
annealing buffer. The washes were performed using
the vacuum station according to the manufacturer’s in-
struction. For annealing the samples to sequencing
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2 minutes and then left to cool at room temperature for
5 minutes. Plates were then ready for processing in the
PyroMarkQ96 instrument.Pyrosequencing
Pyrosequencing of the purified single stranded PCR pro-
ducts and CpG site quantification was accomplished by
the PyroMarkQ96 and related software (Qiagen). The se-
quence to analyse was TTAYGGTYGYGGTTYGGGGT
YGGGTAGAGGAGGTG and contained the densest re-
gion of CpG sites within our amplicon. The five CpG
sites were investigated in both neoplastic and corre-
sponding non-neoplastic tissues. Each CpG site was
assigned a percentage of methylation by evaluating the
C/T ratio. The average percentage of methylation across
these 5 CpG sites was obtained. The tumor-specific
methylation was calculated by subtracting the average%
methylation of the normal mucosa from the average%
methylation of tumor. Representative pyrograms are
shown in Figure 1.Figure 1 Representative pyrograms with PyroMarkQ96 showing perc
Highly methylated tumor sample with an average methylation percentage
non-methylated non-tumoral tissue from the same patient as in A with theBackground and PCR cycle number
Taking into consideration that CDKN2A methylation
may occur in normal tissues (A-type methylation) as an
age-dependent phenomenon, an appropriate cut-off
score should be assigned above which “hypermethyla-
tion” can be defined [5]. To investigate this, the experi-
mental background of the pyrosequencing method using
samples prepared by mixing DNA obtained from periph-
eral blood leukocytes of healthy donors (unmethylated)
and from commercially available 100% methylated DNA
(Zymo Research D5011) was tested. Different concentra-
tions of methylated p16 DNA were obtained by perform-
ing serial dilutions. The measured percentage of
methylation was analysed by pyrosequencing using the
PyroMarkQ24 instrument and compared to each theor-
etical percentage (ranging from 0-100%) (Figure 2A).
The effect of different amplification conditions (30 to 50
PCR cycles) was also tested. A strong correlation be-
tween the measured and theoretical percentage methyla-
tion was observed. For 30 PCR cycles, the correlation
was acceptable but a higher background methylation,
up to 20%, was observed. With 35 cycles or more,entage of methylation at each of five CpG sites evaluated. A)
of (82% + 87% + 79% + 82% + 82%)/5 = 82.4%. B) Corresponding
following methylation pattern: 2%, 2%, 0%, 0%, and 0%.
Figure 2 A): Serial dilutions of 100% and 0% methylated DNA were combined and pyrosequencing used to analyse the measured and
theoretical percentage of methylated DNA as a function of the number of PCR cycles. A strong correlation between the measured and
theoretical percentage of methylation was observed, particularly for PCR cycle numbers of 35 or more. B) Influence on methylation background
as a function of PCR cycle numbers. C) In contrast to pyrosequencing, only a poor correlation between the measured and theoretical percentage
of methylation was observed using methylation-specific PCR (MSP) which also showed a considerable dependency on PCR cycle number. D)
Comparison of measured and theoretical percentage of methylation for 40 and 50 PCR cycles obtained using pyrosequencing and MSP.
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consistently observed (Figure 2B); 45 cycles showed the
least degree of background.
Comparison with methylation-specific PCR
The percentage of methylation for the same samples was
also evaluated using methyl specific primer (MSP)Table 1 Comparison of primers and genomic coordinates use
to Herman et al. [7]
Position/AB060808.1 P
CDS p16/CDKN2A exon 1 192221- > 192072 0
This study F1 192197- > 192176 2
R1_primer 192050- > 192033 1
R2_primer 192077- > 192060 1
Herman F1 192301- > 192278 −
R1 192172- > 192151 4amplification as established by Herman et al. [7]. Table 1
compares the genomic coordinates used in this study
with those described by Herman et al. Interestingly the
results obtained with this method were highly dependent
on the number of PCR cycles performed (Figure 2C).
The percentage of methylation given by this method was
consistently higher than expected. For example,d in this study for methylation-specific PCR in comparison
osition / Start codon Sequence
- > 149 ATGGAGCCGG. . ...GCCGATCCAG
4 - > 45 ATGGAGCCTTCGGCTGACTGGC
71 - > 188 CCCGCCATCCCCTGCTCC
44 - > 161 CCCTCTACCCACCTGGAT
80 - > −57 TCACCAGAGGGTGGGGCGGACCGC
9 - > 70 TTAACAAAAAAAAAAAACTAAACTCCTC
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status of >80% although the percentage of the sample is
2%. A direct comparison between the methylation status
obtained using pyrosequencing and MSP amplification
for 40 and 50 amplification cycles was represented in
Figure 2D.
Statistical Analysis
Differences in the percentage of methylation between
normal and tumor tissues at each CpG site were ana-
lysed using the non-parametric Wilcoxon’s Rank Sum
test. Associations between methylation and categorical
clinico-pathological features were investigated using the
Chi-Square or Fisher’s Exact tests. For age and tumor
size, differences between CDKN2A methylation positive
and negative tumors were analysed using Wilcoxon’s
Rank Sum Test. Kaplan-Meier plots and the log-rank
test was used to analyse differences in survival time be-
tween patients with methylation positive and negative
tumors un a univariate setting. Cox proportional hazards
regression models were used in a multivariable setting to
test the independent contribution of each variable to
outcome after adjustment for the remaining potential
confounding variables. Hazard ratios (HR) and 95% con-
fidence intervals were used to determine the effect of
each variable on outcome.
Results
CpG site-specific analysis of CDKN2A
In a first step, colorectal cancers and corresponding nor-
mal tissue from 432 patients were evaluated for
CDKN2A methylation. Five different CpG sites were
assessed. In 10 cases, no evaluation of tumor could beFigure 3 A) Mean percent-methylation± standard deviation of each C
all sites was 8.3% in normal mucosa and 17.6% in colorectal cancer. The pe
larger in the tumor compared with normal tissue. B) Distribution of methyl
percentage of methylation in normal tissues than in tumor. Most cases sho
cases were considered methylation positive (at least 20% more methylationmade; the total number of patients successfully evaluated
was thus 422. The mean ± SD percentage methylation at
each CpG site was analysed in both normal mucosa and
tumor. Results are shown in Figure 3A. In normal tissue,
at each site percentage of methylation was 9.9%, 9.2%,
4.2%, 11% and 6.6%, respectively, while almost twice that
in tumor, namely 20.9%, 18.8%, 13.6%, 20.3% and 14.8%.
Tumors were significantly more methylated than normal
tissues at each CpG site and on average across all sites
(normal: 8.3% versus tumor: 17.6%) (p < 0.0001, all). No
site was specifically correlated with patient age in nor-
mal tissue.
Methylation differences between tumor and normal
mucosa
The distribution of CDKN2A methylation differences be-
tween tumor and normal mucosa are shown in
Figure 3B. Considering a background methylation rate of
10%, (see 2.7), 92.2% of all cases had equal or greater
methylation in tumor compared to normal tissue, while
33 cases (7.8%) were more highly methylated in normal
mucosa. Using a threshold value of 20% difference be-
tween tumor and normal tissue, 87 patients (20.6%) were
considered methylation-positive.
CDKN2A methylation and clinico-pathological and
molecular data
Methylation of CDKN2A in colorectal cancers was sig-
nificantly more frequent in right-sided colon cancers (p
< 0.0001), as well as those with mucinous histology (p =
0.0209), higher tumor grade (p < 0.0001) and lymph
node metastasis (p = 0.0335). Although methylation was
not associated with KRAS mutation (p = 0.565), a strongpG site within the region analysed. The average methylation across
rcent-methylation at each CpG site is significantly (p < 0.0001, all)
ation in normal tissues and tumor. 7.8% of all cases should a greater
wed slightly more methylation in tumor than normal while 20.6% of
in tumor).
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methylation was observed (p < 0.0001). Specifically 31.2%
of methylated cases showed BRAF mutation in compari-
son to only 5.9% of negative cases. In addition, methyla-
tion was found more frequently in MSI-H (23.5%) than
MSS/MSI-L (13.4%) cancers (p = 0.0252) (Table 2).
Effect of CDKN2A methylation on survival
The prognostic effect of CDKN2A could be assessed in
all 422 patients. Methylation led to a strong negative ef-
fect on survival time (p = 0.0003, log-rank; Figure 4A).
This is additionally highlighted by a HR (95%CI) of 1.6
(1.2-2.1) indicating that patients with methylation-
positive tumors have a 60% increased risk of death in
comparison to methylation-negative patients. This as-
sociation is maintained in patients with MSS/MSI-L
cancers (p = 0.0001; Figure 4B) whereas the effect
was non-significant in patients with MSI-H tumorsTable 2 Association of CDKN2A methylation and clinico-patho
Feature CDK
Neg
Age Mean (range)
Tumor size Mean (range)
Tumor location Left-sided
Right-sided
Gender Female
Male
Histological subtype Non-mucinous
Mucinous
Tumor grade G1-2
G3
pT classification pT1-2
pT3-4
pN classification pN0
pN1-2
Vascular invasion Absent
Present
Invasive margin Pushing
Infiltrating
Peritumoral lymphocytic inflammation Absent
Present
KRAS (codon 12/13) Wild-type
Mutation
BRAF (codon V600E) Wild-type
Mutation
MSI status MSS/MSI-L
MSI-H(p = 0.095; Figure 4C). However, of the 19 patients
with MSI-H/CDKN2A methylation positive cancers,
14 (74%) died of disease, in comparison to 20/42
(47.6%) of patients with MSI-H/CDKN2A methylation
negative cancers.
Next we stratified the survival effect of CDKN2A
methylation by BRAF status. In both BRAF WT (p =
0.0291) and BRAF mutated (p = 0.0121) tumors,
CDKN2A methylation positivity had a significant and
unfavourable effect on survival time (Figure 4 D, E).
We further performed multivariate analysis of CDKN2A
using two different models. In the first, we analysed
CDKN2A methylation status along with standard clinic-
pathological data including age, pT, and pN classifications.
In a second, we evaluated CDKN2A methylation along
with MSS and BRAF status. In both models, methylation
positivity maintained its significance unfavourable effect
on outcome (Table 3).logical features in colorectal cancers (n = 422)
N2A N(%) P-value
ative (335; 79.4%) Methylated (87; 20.6%)
69.3 (37–95) 68.8 (39–89) 0.7292
49.3 (5–160) 53.5 (4–170) 0.1265
232 (69.5) 40 (46.5) <0.0001
102 (30.5) 46 (53.5)
181 (54.0) 48 (55.2) 0.849
154 (46.0) 39 (44.8)
19 (5.7) 11 (12.6) 0.0209
316 (94.3) 76 (87.4)
317 (96.7) 74 (85.1) <0.0001
11 (3.4) 13 (14.9)
75 (22.9) 14 (16.1) 0.1711
253 (77.1) 73 (83.9)
180 (55.9) 37 (43.0) 0.0335
142 (44.1) 49 (57.0)
238 (72.6) 54 (62.1) 0.0568
90 (27.4) 33 (37.9)
101 (30.9) 21 (24.4) 0.242
226 (69.1) 65 (75.6)
251 (76.5) 66 (75.9) 0.897
77 (23.5) 21 (24.1)
227 (69.2) 58 (72.5) 0.565
101 (30.8) 22 (27.5)
287 (94.1) 53 (68.8) <0.0001
18 (5.9) 24 (31.2)
272 (86.6) 62 (76.5) 0.0252
42 (13.4) 19 (23.5)
Figure 4 Kaplan-Meier survival curves showing the unfavorable prognostic impact of CDKN2A methylation positivity in (A) all patients
and in cases with (B) microsatellite stable (MSS/MSI-L), (C) microsatellite instability-high (MSI-H), (D) BRAF wild-type (WT) and (E) BRAF
mutation.
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Since methylation of CDKN2A occurs more frequently
in MSI-H and shows the typical features characteristic of
unstable cancers, we evaluated the relationship between
CDKN2A methylation and prognostic factors in both
MSS/MSI-L and MSI-H cases. Among patients with
MSS/MSI-L tumors, methylation was still associated
with right-sided disease (p = 0.0125), higher-tumor grade
(p < 0.0001), lymph node positivity (p = 0.0207), and
BRAF mutation (p < 0.0001. In contrast, in the MSI-H
setting, methylation was linked to right-sided location (p
= 0.013), higher pT classification (p = 0.0093), vascular
invasion (p = 0.0326), the infiltrating growth pattern (p
= 0.0281), KRAS mutation (p = 0.0356) and BRAF muta-
tion (p = 0.0098) (Table 4).Table 3 Multivariate survival analysis of CDKN2A methylation
MODEL 1
HR (95%CI) P-value
CDKN2A Negative 1.0 0.0416
Methylated 1.36 (1.1-1.8)
Age Baseline 1.0
1-year 1.04 (1.02-1.05) <0.0001
pT pT1-2 1.0 <0.0001
pT3-4 1.98 (1.3-2.9)
pN pN0 1.0 <0.0001
pN1-2 2.52 (1.9-3.3)Discussion
In this study we evaluated CDKN2A methylation using
pyrosequencing on a large cohort of 422 patients with
colorectal cancer. Using both primary tumors and
matched non-neoplastic tissues, we analyzed individual
CpG sites and different amplification conditions. Add-
itionally, we highlight the negative and independent
prognostic effect of CDKN2A methylation on prognosis
in patients with colorectal cancer using pyrosequencing.
Our results show acceptable levels (<10%) of background
CDKN2A methylation with ≥35 PCR cycles; lowest levels
were reached at 45 cycles. The predicted and observed
degrees of methylation found after serial dilutions with
methylated and non-methylated DNA show a tight correl-
ation at these amplification conditions, while even lowin colorectal cancer
MODEL 2
HR (95%CI) P-value
CDKN2A Negative 1.0 0.0021
Methylated 1.66 (1.2-2.3)
MSI MSS/MSI-L 1.0 0.0273
MSI-H 0.63 (0.4-0.9)
BRAF Wild-type 1.0 0.2165
Mutation 1.32 (0.9-2.0)
Table 4 Association of CDKN2A methylation and clinico-pathological features stratified by microsatellite instability
(MSI) status
Feature CDKN2A in MSS/MSI-L (n;%) P-value CDKN2A in MSI-H (n;%) P-value
Negative Positive Negative Positive
(n = 272; 81.4%) (n = 62; 18.6%) (n = 42; 68.9%) (n = 19; 31.2%)
Age Mean (range) 69.5 (40–95) 69.9 (44–88) 0.788 68.4 (45–87) 68.2 (50–89) 0.9897
Tumor size Mean (range) 48.0 (5–130) 49.8 (4–105) 0.523 54.9 (19–160) 62.8 (15–170) 0.3737
Tumor location Left-sided 193 (71.2) 34 (54.8) 0.0125 24 (57.1) 4 (22.2) 0.013
Right-sided 78 (28.8) 28 (45.2) 18 (42.9) 14 (77.8)
Gender Female 149 (54.8) 34 (54.8) 0.9932 20 (47.6) 10 (52.6) 0.7169
Male 123 (45.2) 28 (45.2) 22 (52.4) 9 (47.4)
Histological subtype Non-mucinous 253 (93.0) 54 (87.1) 0.1142 39 (92.9) 16 (84.2) 0.2863
Mucinous 16 (5.9) 8 (12.9) 3 (7.1) 2 (10.5)
Tumor grade G1-2 261 (98.1) 54 (87.1) <0.0001 37 (88.1) 14 (73.7) 0.2608
G3 5 (1.9) 8 (12.9) 5 (11.9) 5 (26.3)
pT classification pT1-2 59 (22.1) 13 (21.0) 0.8354 12 (28.6) 0 (0.0) 0.0093
pT3-4 207 (77.8) 49 (79.0) 30 (71.4) 19 (100.0)
pN classification pN0 140 (53.4) 23 (37.1) 0.0207 26 (66.7) 10 (52.6) 0.3012
pN1-2 122 (46.6) 39 (62.9) 13 (33.3) 9 (47.4)
Vascular invasion Absent 186 (69.9) 37 (59.7) 0.1193 35 (83.3) 11 (57.9) 0.0326
Present 80 (30.1) 25 (40.3) 7 (16.7) 8 (42.1)
Invasive margin Pushing 69 (26.0) 12 (19.7) 0.2996 26 (61.9) 6 (31.6) 0.0281
Infiltrating 196 (74.0) 49 (80.3) 16 (38.1) 13 (68.4)
Peritumoral lymphocytic
inflammation
Absent 211 (79.3) 51 (82.3) 0.6037 27 (64.3) 13 (68.4) 0.7529
Present 55 (20.7) 11 (17.7) 15 (35.7) 6 (31.6)
KRAS (codon 12/13) Wild-type 185 (69.0) 41 (68.3) 0.9161 26 (65.0) 14 (93.3) 0.0356
Mutation 83 (31.0) 19 (31.7) 14 (35.0) 1 (6.7)
BRAF (codon V600E) Wild-type 245 (96.8) 42 (75.0) <0.0001 30 (79.0) 8 (44.4) 0.0098
Mutation 8 (3.2) 14 (25.0) 8 (21.0) 10 (55.6)
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high number of amplification cycles is often necessary for
pyrosequencing. Since both biotinylated template strands
and unincorporated biotinylated primers can be captured
on the streptavidin-coated beads, a high number of PCR
cycles ensures that the biotinylated primer does not itself
act as an additional sequencing primer thereby interfering
with the subsequent sequencing reaction [6].
Although the average percentage of methylation in
non-neoplastic tissues was <10% across all CpG sites, in
some cases it could reach >90%. This non-negligible
methylation pattern suggests that the normal corre-
sponding mucosa must be used as a control in the as-
sessment of CDKN2A hypermethylation in colorectal
cancers. In fact, nearly 10% of all cases showed greater
methylation in the adjacent non-neoplastic regions than
in the carcinoma. Not only has age-dependent methyla-
tion been recognized as an important physiological
process but recent studies show further that CpG islandmethylation in normal colorectal mucosa may also be
related to ethnicity, tumor location and intake of sup-
plements such as folic acid [5,8]. This indicates that
methylation patterns in normal colorectal mucosa can-
not be ignored supporting our decision to use normal
tissue as a control in this study.
Although several different options were considered for
setting a threshold value for methylation positivity, we
chose to consider cases with at least 20% methylation
difference between tumor and normal tissue as methyla-
tion positive. The number of positive cases, namely 20%
of patients, falls within the range previously described
[4]. Since background methylation in both tumor and
normal tissues may reach 10%, setting a cut-off at 20%
ensures that only methylated cases be assigned as posi-
tive. In addition, since we included cases enriched for
>70% tumor content, it is possible that a few samples
containing sufficient non-neoplastic tissue may be mis-
classified as methylation negative, i.e., false-negatives.
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threshold values for methylation positivity using pyrose-
quencing. Vasiljevic and colleagues found an optimal
cut-off of 35% for methylation in prostate cancers using
data resampling and statistical methods [9]. Several
groups have assigned positivity to cases with a methyla-
tion density >15% [10-13]. In lymphoma, cut-offs for
CDKN2A methylation positivity were based on receiver
operating characteristics (ROC) curves and compared to
the median and mean methylation levels ultimately cate-
gorized as negative, low, intermediate and high when
<5%, 5-25%, 25-40% and >40% methylation was found,
respectively [14]. Others have used the mean and stand-
ard deviation as a basis for cut-off value determination
for CIMP-related markers [15]. These methods have
advantages and drawbacks. Methods based on the mean
and SD may be suboptimal since the presence of out-
liers, as was seen in our study, may have a considerable
impact on skewing the distribution of the methylation
data in normal tissues in particular. Cut-off scores
derived after the analyses of entire cohorts may be disad-
vantageous in that they are not generalizable to other
datasets. A cut-off score derived from ROC curve ana-
lysis is often advantageous as it may have the most clin-
ically relevant value for a specific endpoint of interest,
such as survival. It does nonetheless test the entire range
of possible methylation values including those that may
be irrelevant. Applying ROC curve analysis to our data
here, we found an ‘optimal’ difference of 5% to be suffi-
cient. This value, although statistically optimal is less
compatible with the biological relevance.
In our series, CDKN2A methylation positivity corre-
lated with more frequent right-sided disease, mucinous
histology, tumor grade as well as with MSI, BRAF muta-
tion and with KRAS mutation in the MSI setting only.
This finding is in line with other studies showing the as-
sociation of methylation with “classical” features of MSI
and high-level CIMP [4]. Poorer prognosis is found in
patients with CDKN2A methylation positive tumors re-
gardless of BRAF gene status. Additionally, unfavorable
survival time was again particularly observed in patients
with MSS disease. These results are in line with findings
from Kim et al. using pyrosequencing (n = 131), Mitomi
and colleagues using q-MSP (n = 151), Liang et al. using
MSP (n = 84) cases and Maeda and coworkers using q-
MSP (n = 90) showing either a negative prognostic effect
of CDKN2A methylation in univariate and/or multivari-
ate analysis [16-19].
Conclusion
To conclude, our study indicates that pyrosequencing for
CDKN2A methylation analysis is robust even at low
methylation levels and may be particularly suited for
large solid tumor samples like colorectal cancer.However, the non-negligible methylation occurring in
the adjacent normal colorectal mucosa may confound
the assessment of tumor-specific CDKN2A hypermethy-
lation suggesting that corresponding non-neoplastic tis-
sue should be used as a control. This finding is certainly
not only restricted to CDKN2A but should perhaps be
considered for other genes that may be strongly methy-
lated in normal tissues as well. The independent and
highly adverse prognostic effect of CDKN2A methylation
using the approach described here suggests that pro-
spective analysis of this biomarker is warranted.
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